Addition of a cross-ancestry polygenic risk score to the standard of care clinical risk predictor tool improved breast cancer risk assessment across multiple ancestries MENLO
The oversubscribed series B financing led by Healthcare Venture Partners, added SoftBank Corp.and Natera to existing investors– Sequoia Capital, Foresite Capital, Founders Fund, among others
“A dearth of genome-wide association studies focused on non-European populations, plus issues related to applying polygenic risk scores in populations with multiple ancestries, has spurred
“NEW YORK – Personalized genomics company MyOme presented data at the recent American Society of Clinical Oncology conference demonstrating its ability to train and validate
MyOme Presents New Data at ASCO 2022 on Cross-ancestry Polygenic Risk Score for Breast CancerStudy highlights potential of Polygenic Risk Scores (PRS) to improve breast
“A Silicon Valley company has designed a technique to decipher the genetic code of a tiny embryo and calculate its future risk of cancer, diabetes
“A California company says it can decipher almost all the DNA code of a days-old embryo created through in vitro fertilization (IVF)—a challenging feat because
“The ability to assess disease-related polygenic scores and rare variants in preimplantation embryos may be improved through whole-genome reconstruction (WGR) informed by embryo genotypes and
